{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:21:01Z","timestamp":1767990061533,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00404-019-05131-x","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T15:05:34Z","timestamp":1554217534000},"page":"1597-1605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system"],"prefix":"10.1007","volume":"299","author":[{"given":"Rafaella C.","family":"Rebelo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estephania","family":"Pignaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valeria Bahamondes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian T. L.","family":"Costallat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Bahamondes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5872-0017","authenticated-orcid":false,"given":"Arlete","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"5131_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"5131_CR2","first-page":"247","volume":"58","author":"RA Williamson","year":"1981","unstructured":"Williamson RA, Karp LE (1981) Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol 58:247\u2013250","journal-title":"Obstet Gynecol"},{"key":"5131_CR3","first-page":"709","volume":"20","author":"A Ossandon","year":"2002","unstructured":"Ossandon A, Cassar\u00e0 EA, Priori R, Valesini G (2002) Thalidomide: focus on its employment in rheumatologic diseases. Clin Exp Rheumatol 20:709\u2013718","journal-title":"Clin Exp Rheumatol"},{"key":"5131_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2174\/1871520616666161206150421","volume":"17","author":"P Rengasamy","year":"2017","unstructured":"Rengasamy P (2017) Congenital malformations attributed to prenatal exposure to cyclophosphamide. Anticancer Agents Med Chem 17:1211\u20131227","journal-title":"Anticancer Agents Med Chem"},{"key":"5131_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/ard.51.2.160","volume":"51","author":"JL Vianna","year":"1992","unstructured":"Vianna JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, Hughes GR (1992) Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 51:160\u2013161","journal-title":"Ann Rheum Dis"},{"key":"5131_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/03009740510026913","volume":"35","author":"T Gould","year":"2006","unstructured":"Gould T, Tikly M, Asherson R, Loizou S, Singh S (2006) Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 35:29\u201334","journal-title":"Scand J Rheumatol"},{"key":"5131_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MD.0b013e31829cae47","volume":"92","author":"CC Mok","year":"2013","unstructured":"Mok CC, Chan PT, Ho LY, Yu KL, To CH (2013) Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort study. Medicine (Baltim) 92:217\u2013222","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"5131_CR8","doi-asserted-by":"publisher","first-page":"e110242","DOI":"10.1371\/journal.pone.0110242","volume":"24","author":"JS Franco","year":"2014","unstructured":"Franco JS, Molano-Gonz\u00e1lez N, Rodr\u00edguez-Jim\u00e9nez M, Acosta-Ampudia Y, Mantilla RD, Amaya-Amaya J et al (2014) The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians. PLoS One 24(9):e110242","journal-title":"PLoS One"},{"key":"5131_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295\u2013306","journal-title":"J Thromb Haemost"},{"key":"5131_CR10","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010\u20132021","journal-title":"N Engl J Med"},{"key":"5131_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","volume":"76","author":"GJ Pons-Estel","year":"2017","unstructured":"Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A (2017) The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 76:10\u201320","journal-title":"J Autoimmun"},{"key":"5131_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","volume":"19","author":"B Griffiths","year":"2005","unstructured":"Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685\u2013708","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"5131_CR13","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1056\/NEJMoa050817","volume":"353","author":"J S\u00e1nchez-Guerrero","year":"2005","unstructured":"S\u00e1nchez-Guerrero J, Uribe AG, Jim\u00e9nez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539\u20132549","journal-title":"N Engl J Med"},{"key":"5131_CR14","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550\u20132558","journal-title":"N Engl J Med"},{"key":"5131_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N et al (2017) EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 76:476\u2013485","journal-title":"Ann Rheum Dis"},{"key":"5131_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.contraception.2004.07.009","volume":"70","author":"J Conard","year":"2004","unstructured":"Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC (2004) Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 70:437\u2013441","journal-title":"Contraception"},{"key":"5131_CR17","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.thromres.2012.02.042","volume":"129","author":"MA Blanco-Molina","year":"2012","unstructured":"Blanco-Molina MA, Lozano M, Cano A, Cristobal I, Pallardo LP, Lete I (2012) Progestin-only\u00a0contraception\u00a0and\u00a0venous thromboembolism. Thromb Res 129:e257\u2013e262","journal-title":"Thromb Res"},{"key":"5131_CR18","doi-asserted-by":"publisher","first-page":"b2890","DOI":"10.1136\/bmj.b2890","volume":"339","author":"\u00d8 Lidegaard","year":"2009","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890","journal-title":"BMJ"},{"key":"5131_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","volume":"94","author":"NK Tepper","year":"2016","unstructured":"Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM (2016) Progestin only contraception and thromboembolism: a systematic review. Contraception 94:678\u2013700","journal-title":"Contraception"},{"key":"5131_CR20","unstructured":"World Health Organization (2015) Medical eligibility criteria for contraceptive use\u20145th ed. Switzerland. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/181468\/1\/9789241549158_eng.pdf?ua=1\n                    \n                  . Accessed 01 June 2018"},{"key":"5131_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630\u2013640","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"5131_CR22","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1002\/acr.20572","volume":"63","author":"J Romero-Diaz","year":"2011","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R (2011) Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken) 63(Suppl 11):S37\u2013S46","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"5131_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0010-7824(98)00041-9","volume":"57","author":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","year":"1998","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1998) Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 57(5):315\u2013324","journal-title":"Contraception"},{"key":"5131_CR24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1161\/ATVBAHA.110.211482","volume":"30","author":"Vlieg A Hylckama van","year":"2010","unstructured":"van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR (2010) The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 30:2297\u20132300","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5131_CR25","doi-asserted-by":"publisher","first-page":"e4944","DOI":"10.1136\/bmj.e4944","volume":"345","author":"S Mantha","year":"2012","unstructured":"Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI (2012) Assessing the risk of venous thromboembolic events in women taking progestin only contraception: a meta-analysis. BMJ 345:e4944","journal-title":"BMJ"},{"key":"5131_CR26","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","volume":"366","author":"\u00d8 Lidegaard","year":"2012","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257\u20132266","journal-title":"N Engl J Med"},{"key":"5131_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3899\/jrheum.150506","volume":"43","author":"A Hinojosa-Azaola","year":"2016","unstructured":"Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, Nu\u00f1ez-Alvarez CA, Cicero-Casarrubias A, Ocampo-Torres MC et al (2016) Venous and arterial thrombotic events in systemic lupus erythematosus. J Rheumatol 43:576\u2013586","journal-title":"J Rheumatol"},{"key":"5131_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10067-007-0721-z","volume":"27","author":"K Choojitarom","year":"2008","unstructured":"Choojitarom K, Verasertniyom O, Totemchokchyakarn K, Nantiruj K, Sumethkul V, Janwityanujit S (2008) Lupus nephritis and Raynaud\u2019s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 27:345\u2013351","journal-title":"Clin Rheumatol"},{"key":"5131_CR29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","volume":"8","author":"R Urbanus","year":"2009","unstructured":"Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998\u20131005","journal-title":"Lancet Neurol"},{"key":"5131_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","volume":"133","author":"A Matyja-Bednarczyk","year":"2014","unstructured":"Matyja-Bednarczyk A, Swad\u017aba J, Iwaniec T, Sanak M, Dziedzina S, \u0106miel A et al (2014) Risk factors for arterial thrombosis in antiphospholipid syndrome. Thromb Res 133:173\u2013176","journal-title":"Thromb Res"},{"key":"5131_CR31","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/art.38520","volume":"66","author":"R Kaiser","year":"2014","unstructured":"Kaiser R, Tang LF, Taylor KE, Sterba K, Nititham J, Brown EE et al (2014) A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. Arthritis Rheumatol 66:1882\u20131887","journal-title":"Arthritis Rheumatol"},{"key":"5131_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0378-5122(96)00994-2","volume":"24","author":"H Kuhl","year":"1996","unstructured":"Kuhl H (1996) Effects of progestogens on haemostasis. Maturitas 24:1\u201319","journal-title":"Maturitas"},{"issue":"6","key":"5131_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2265.1982.tb01625.x","volume":"17","author":"CG Nilsson","year":"1982","unstructured":"Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T (1982) Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 17(6):529\u2013536","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5131_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.contraception.2012.01.015","volume":"86","author":"B Seeber","year":"2012","unstructured":"Seeber B, Ziehr SC, Gschlie\u03b2er A, Moser C, Mattle V, Seger C et al (2012) Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 86:345\u2013349","journal-title":"Contraception"},{"key":"5131_CR35","first-page":"1","volume":"19","author":"MB Brito","year":"2018","unstructured":"Brito MB, Casqueiro JS, Alves FSS, Lopes JB, Alves RDMS, Santiago M (2018) Low prevalence of contraceptive use among Brazilian women of reproductive age with systemic lupus erythematosus. J Obstet Gynaecol 19:1\u20134","journal-title":"J Obstet Gynaecol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-019-05131-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05131-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:19:52Z","timestamp":1585696792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-019-05131-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5131"],"URL":"https:\/\/doi.org\/10.1007\/s00404-019-05131-x","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"26 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper. LB received honorarium to be a member of an advisory board and has been an invited speaker at scientific meetings for Bayer Healthcare Pharmaceuticals. He is a member of the ICA Foundation without remuneration. The LNG-IUS were donated by the International Contraceptive Access (ICA) Foundation, Turku, Finland, under an unrestricted grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Since it was a retrospective study with a review of medical records, the waiver of signature in the consent form was requested and approved in the evaluation of the project.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}